ZOMEDICA CORP(NYSEARCA:ZOM) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to ZOM. ZOM was compared to 188 industry peers in the Health Care Equipment & Supplies industry. While ZOM has a great health rating, there are worries on its profitability. ZOM does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ZOM has reported negative net income.

In the past year ZOM has reported a negative cash flow from operations.

In the past 5 years ZOM always reported negative net income.

ZOM had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -29.05%, ZOM is in line with its industry, outperforming 43.16% of the companies in the same industry.

ZOM's Return On Equity of -30.66% is in line compared to the rest of the industry. ZOM outperforms 57.37% of its industry peers.

		Industry Rank	Sector Rank
ROA	-29.05%
ROE	-30.66%
ROIC	N/A

ROA(3y)-8.76%

ROA(5y)-104.96%

ROE(3y)-9.18%

ROE(5y)-199.7%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ZOM's Gross Margin of 69.64% is fine compared to the rest of the industry. ZOM outperforms 79.47% of its industry peers.

The Profit Margin and Operating Margin are not available for ZOM so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	69.64%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ZOM does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ZOM remains at a similar level compared to 1 year ago.

ZOM has more shares outstanding than it did 5 years ago.

There is no outstanding debt for ZOM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 3.68 indicates that ZOM is not in any danger for bankruptcy at the moment.

ZOM's Altman-Z score of 3.68 is fine compared to the rest of the industry. ZOM outperforms 72.63% of its industry peers.

There is no outstanding debt for ZOM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	3.68

ROIC/WACCN/A

WACC8.9%

2.3 Liquidity

ZOM has a Current Ratio of 10.82. This indicates that ZOM is financially healthy and has no problem in meeting its short term obligations.

ZOM's Current ratio of 10.82 is amongst the best of the industry. ZOM outperforms 92.63% of its industry peers.

A Quick Ratio of 10.15 indicates that ZOM has no problem at all paying its short term obligations.

ZOM's Quick ratio of 10.15 is amongst the best of the industry. ZOM outperforms 92.63% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	10.82
Quick Ratio	10.15

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ZOM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -57.89%.

Looking at the last year, ZOM shows a quite strong growth in Revenue. The Revenue has grown by 11.33% in the last year.

EPS 1Y (TTM)-57.89%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-900%

Revenue 1Y (TTM)11.33%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%10.29%

3.2 Future

Based on estimates for the next years, ZOM will show a decrease in Earnings Per Share. The EPS will decrease by -7.13% on average per year.

ZOM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.91% yearly.

EPS Next Y-110.78%

EPS Next 2Y-14.78%

EPS Next 3Y-5.84%

EPS Next 5Y-7.13%

Revenue Next Year10.67%

Revenue Next 2Y19.02%

Revenue Next 3Y22.19%

Revenue Next 5Y23.91%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZOM. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZOM. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as ZOM's earnings are expected to decrease with -5.84% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-14.78%

EPS Next 3Y-5.84%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ZOM!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ZOMEDICA CORP

NYSEARCA:ZOM (3/4/2025, 8:08:11 PM)

0.0973

0 (-0.21%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)03-13 2025-03-13/amc

Earnings (Next)05-07 2025-05-07

Inst Owners9.39%

Inst Owner Change-92.87%

Ins Owners0.74%

Ins Owner Change5.01%

Market Cap95.35M

Analysts80

Price Target0.26 (167.21%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-23.83%

Min Revenue beat(2)-27.36%

Max Revenue beat(2)-20.3%

Revenue beat(4)1

Avg Revenue beat(4)-17.04%

Min Revenue beat(4)-27.36%

Max Revenue beat(4)3.78%

Revenue beat(8)1

Avg Revenue beat(8)-16.36%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)-380%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-19.35%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	3.57
P/FCF	N/A
P/OCF	N/A
P/B	0.47
P/tB	0.9
EV/EBITDA	N/A

EPS(TTM)-0.03

EYN/A

EPS(NY)-0.03

Fwd EYN/A

FCF(TTM)-0.03

FCFYN/A

OCF(TTM)-0.02

OCFYN/A

SpS0.03

BVpS0.21

TBVpS0.11

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-29.05%
ROE	-30.66%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	69.64%
FCFM	N/A

ROA(3y)-8.76%

ROA(5y)-104.96%

ROE(3y)-9.18%

ROE(5y)-199.7%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.12

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	86.87%
Cap/Sales	25.37%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	10.82
Quick Ratio	10.15
Altman-Z	3.68

F-Score4

WACC8.9%

ROIC/WACCN/A

Cap/Depr(3y)120.38%

Cap/Depr(5y)90.3%

Cap/Sales(3y)29.66%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-57.89%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-900%

EPS Next Y-110.78%

EPS Next 2Y-14.78%

EPS Next 3Y-5.84%

EPS Next 5Y-7.13%

Revenue 1Y (TTM)11.33%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%10.29%

Revenue Next Year10.67%

Revenue Next 2Y19.02%

Revenue Next 3Y22.19%

Revenue Next 5Y23.91%

EBIT growth 1Y-50.99%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-88.74%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-70%

OCF growth 3YN/A

OCF growth 5YN/A

ZOMEDICA CORP (ZOM) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens